FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

Mixed results for Roche drugs in prostate cancer and COVID-1...

Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug achieved only one of its targets and its inflammatory

Mereo raises $70m as TIGIT cancer drug progresses in clinic

Mereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. 

FDA clears emergency use of Roche test for COVID-19 'cytokin...